Sensei Biotherapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Sensei Biotherapeutics is John Celebi, benoemd in Feb2018, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.01M, bestaande uit 52.6% salaris en 47.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde $ 33.39K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 3.8 jaar.

Belangrijke informatie

John Celebi

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris	52.6%
Dienstverband CEO	6.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16

Analyse CEO-vergoeding

Hoe is John Celebi's beloning veranderd ten opzichte van Sensei Biotherapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$1m	US$532k	-US$34m
Sep 30 2023	n/a	n/a	-US$39m
Jun 30 2023	n/a	n/a	-US$45m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$2m	US$513k	-US$49m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$42m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$7m	US$487k	-US$37m
Sep 30 2021	n/a	n/a	-US$33m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$2m	US$395k	-US$20m

Compensatie versus markt: De totale vergoeding ($USD 1.01M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Celebi (52 yo)

6.8yrs

Tenure

US$1,012,289

Compensatie

Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Celebi	President	6.8yrs	US$1.01m	0.25% $ 33.4k
Edward Van der Horst	Chief Scientific Officer	1.9yrs	US$739.08k	0.14% $ 18.9k
Josiah Craver	Senior VP of Finance	less than a year	geen gegevens	geen gegevens
Lora Pike	Vice President of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Christopher Gerry	Senior VP	2.3yrs	geen gegevens	geen gegevens
Stephanie Krebs	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Aaron Weitzman	Chief Medical Officer	no data	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SNSE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Celebi	President	6.8yrs	US$1.01m	0.25% $ 33.4k
Thomas Ricks	Independent Director	8.9yrs	US$75.56k	1.35% $ 181.3k
William Ringo	Independent Chairman	2.7yrs	US$101.57k	0.063% $ 8.5k
Robert Holmen	Independent Director	7.8yrs	US$73.39k	0.084% $ 11.3k
Richard Ulevitch	Member of Immuno-Oncology Advisory Board	3.5yrs	geen gegevens	geen gegevens
Deneen Vojta	Independent Director	3.8yrs	US$69.32k	0.018% $ 2.4k
James Peyer	Independent Director	4.8yrs	US$68.43k	geen gegevens
Alain Algazi	Member of Immuno-Oncology Advisory Board	no data	geen gegevens	geen gegevens
Maura Gillison	Member of Immuno-Oncology Advisory Board	3.5yrs	geen gegevens	geen gegevens
Kristian Humer	Independent Director	3.3yrs	US$62.24k	0.018% $ 2.4k
Sara Pai	Member of Immuno-Oncology Advisory Board	no data	geen gegevens	geen gegevens
Robert Schreiber	Member of Immuno-Oncology Advisory Board	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SNSE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Sensei Biotherapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Recent updates

Sensei Biotherapeutics, Inc. to Close its Research Site in Rockville, Maryland and Reduce its Workforce by Approximately 46%

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Price target decreased by 13% to US$4.33

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE).

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo

Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

High number of new directors

eSensei Biotherapeutics, Inc. Announces Reduction of Total Workforce

Sensei Biotherapeutics, Inc. Announces Executive Changes

High number of new and inexperienced directors

Sensei Biotherapeutics, Inc. Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apeiron Investment Sends a Letter to Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sensei Biotherapeutics, Inc. Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, A Ph-Selective Vista-Blocking Antibody

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 2500 Value Index

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Price target decreased to US$8.00

High number of new and inexperienced directors

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Price target decreased to US$11.00

Chairman of The Board recently bought US$80k worth of stock

Chairman of The Board recently bought US$136k worth of stock

Chairman of The Board recently bought US$53k worth of stock

Independent Director recently bought US$57k worth of stock

Independent Director recently bought US$250k worth of stock

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer recently sold US$568k worth of stock

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 3000E Growth Index

Sensei Biotherapeutics, Inc. Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

Sensei Biotherapeutics, Inc. announced that it has received $34.5 million in funding from a group of investors

Independent Director recently bought US$143k worth of stock

Independent Director recently bought US$233k worth of stock

Sensei Biotherapeutics Appoints Deneen Vojta to the Board of Directors

Sensei Biotherapeutics, Inc. has completed an IPO in the amount of $133.000988 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd